Full Year 2025 Biocon Ltd Earnings Call Transcript
Key Points
- Biocon Ltd (BOM:532523) reported a 15% year-on-year increase in revenue from operations for Q4, driven by strong growth in Generics, Biosimilars, and Research Services.
- Core EBITDA for the quarter increased by 16% year-on-year, with a healthy operating margin of 31%.
- The Generics segment saw a significant 46% year-on-year growth, bolstered by successful product launches such as lenalidomide in the US.
- Biosimilars revenue for Q4 increased by 9% year-on-year, with strong market share gains for products like Fulphila and Ogivri in the US.
- Research Services achieved an 11% year-on-year revenue increase, crossing the INR1,000 crore threshold for the first time in a quarter.
- Pricing pressure and higher operational expenditure impacted the EBITDA margins for the Generics business, which stood at 12% for FY25.
- The company faces challenges in the US market with the timing of product launches and market share acquisition for new biosimilars.
- There is a substantial net debt of about $1.1 billion as of March 31, which the company plans to address through capital raising.
- The Generics business experienced lumpiness in revenue due to settlement agreements, impacting consistent quarterly performance.
- R&D investments, while crucial for future growth, accounted for a significant portion of revenues, impacting short-term profitability.
(technical difficulty) Steady progress in Biosimilars and ongoing traction in Research Services.
Moving to discuss the financial highlights. For Q4, revenue from operations reached INR4,417 crore, reflecting a solid 15% year-on-year increase on a like-for-like basis and a 16% sequential growth. This growth was driven by a 46% year-on-year growth for Generics, 9% for Biosimilars and 11% for Research Services. Sequentially, all segments reported growth. Generics, particularly, was up 53%, while both Biosimilars and Research Services were up 8%.
Core EBITDA for the quarter stood at INR1,363 crore, a 16% increase from last year with a healthy core operating margin of 31%. R&D investment for the quarter was INR231 crore, accounting for 7% of revenues with, of course, excluding Syngene. Reported EBITDA for Q4 was INR1,150 crore, which is a 60% year-on-year growth on a like-for-like basis. Profit before tax, excluding exceptional items, was INR466 crore, a strong 45% increase on a like-for-like basis.
Now moving to full
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
